Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 5/20 | 0.56 |
| ▸ | THRB | P10828 | 5/20 | 0.56 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5919087 | 0.81 | THRA (0.62) | THRATHRBMAOBDHODHSMN1; SMN2 | |
| SCHEMBL28628175 | 0.77 | THRA (0.54) | THRATHRBDHODHSMN1; SMN2ESR1 | |
| SCHEMBL220153 | 0.77 | MAOA (0.40) | THRATHRBMAOBSMN1; SMN2MAOA | |
| SCHEMBL4722050 | 0.76 | PTGER1 (0.64) | MAOBSMN1; SMN2MAPTCYP2C9CYP2C19 | |
| SCHEMBL29836110 | 0.76 | PTGER1 (0.64) | MAOBSMN1; SMN2MAPTCYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL8641749 | 0.76 | SMN1; SMN2 (0.45) | THRATHRBMAOBDHODHSMN1; SMN2 | |
| SCHEMBL22918087 | 0.76 | MAOB (0.53) | THRATHRBMAOBSMN1; SMN2MAOA | |
| SCHEMBL29660966 | 0.76 | MAOB (0.53) | THRATHRBMAOBSMN1; SMN2MAOA | |
| SCHEMBL29108936 | 0.75 | THRA (0.66) | THRATHRBDHODHSMN1; SMN2ESR1 | |
| SCHEMBL28035507 | 0.75 | THRA (0.55) | THRATHRBDHODHSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | THRA 3966/4885THRB 4083/4885MAOB 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.